Real-World Effectiveness and Safety of Direct-Acting Antivirals in Patients with Chronic Hepatitis C and Epilepsy: An Epi-Ter-2 Study in Poland
Introduction: In Poland, active HCV infection affects between 0.4 and 0.5% of the population, i.e., about 150,000 people, while the number of patients with epilepsy is estimated to be 350,000–400,000. Currently available antiviral therapies show little interaction with neurological drugs. The aim of...
| Main Authors: | , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2023-07-01
|
| Series: | Journal of Personalized Medicine |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2075-4426/13/7/1111 |
| _version_ | 1797588713826418688 |
|---|---|
| author | Monika Pazgan-Simon Jerzy Jaroszewicz Krzysztof Simon Beata Lorenc Marek Sitko Dorota Zarębska-Michaluk Dorota Dybowska Magdalena Tudrujek-Zdunek Hanna Berak Włodzimierz Mazur Jakub Klapaczyński Ewa Janczewska Anna Parfieniuk-Kowerda Robert Flisiak |
| author_facet | Monika Pazgan-Simon Jerzy Jaroszewicz Krzysztof Simon Beata Lorenc Marek Sitko Dorota Zarębska-Michaluk Dorota Dybowska Magdalena Tudrujek-Zdunek Hanna Berak Włodzimierz Mazur Jakub Klapaczyński Ewa Janczewska Anna Parfieniuk-Kowerda Robert Flisiak |
| author_sort | Monika Pazgan-Simon |
| collection | DOAJ |
| description | Introduction: In Poland, active HCV infection affects between 0.4 and 0.5% of the population, i.e., about 150,000 people, while the number of patients with epilepsy is estimated to be 350,000–400,000. Currently available antiviral therapies show little interaction with neurological drugs. The aim of our study was to evaluate the effectiveness and safety of the treatment of chronic HCV infection in patients with coexisting epilepsy. Methods: A total of 184 epilepsy patients were selected from the group of 10,152 HCV-infected patients treated for HCV infection within the Epiter-2 database from 2015 to 2018. Comparing the effectiveness and safety of anti-HCV regimens between the patients with comorbid epilepsy and 3573 patients without comorbidities was our study’s objective. Results: The effectiveness of anti-HCV treatment was high in both the sample and the control group. No statistically significant SVR difference was observed between the sample group, with ITT = 93.5% and mITT = 95.5%, and the control group, with ITT = 95.2% and mITT = 97.5%, regardless of the genotype and the stage of liver disease at the start of therapy. The treatment was safe in patients with epilepsy. Conclusions: The effectiveness and safety of HCV treatment in patients with epilepsy are comparable to those of patients with no significant comorbidities. |
| first_indexed | 2024-03-11T00:55:55Z |
| format | Article |
| id | doaj.art-9f1c660d27b54c3fbfffadb43ebbca63 |
| institution | Directory Open Access Journal |
| issn | 2075-4426 |
| language | English |
| last_indexed | 2024-03-11T00:55:55Z |
| publishDate | 2023-07-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Journal of Personalized Medicine |
| spelling | doaj.art-9f1c660d27b54c3fbfffadb43ebbca632023-11-18T20:03:46ZengMDPI AGJournal of Personalized Medicine2075-44262023-07-01137111110.3390/jpm13071111Real-World Effectiveness and Safety of Direct-Acting Antivirals in Patients with Chronic Hepatitis C and Epilepsy: An Epi-Ter-2 Study in PolandMonika Pazgan-Simon0Jerzy Jaroszewicz1Krzysztof Simon2Beata Lorenc3Marek Sitko4Dorota Zarębska-Michaluk5Dorota Dybowska6Magdalena Tudrujek-Zdunek7Hanna Berak8Włodzimierz Mazur9Jakub Klapaczyński10Ewa Janczewska11Anna Parfieniuk-Kowerda12Robert Flisiak13Department of Infectious Diseases, Regional Specialistic Hospital, 50-149 Wrocław, PolandDepartment of Infectious Diseases and Hepatology, Medical University of Silesia in Katowice, 41-902 Bytom, PolandDepartment of Infectious Diseases, Regional Specialistic Hospital, 50-149 Wrocław, PolandDepartment of Infectious Diseases, Pomeranian Center of Infectious Diseases, University of Gdansk, 80-210 Gdańsk, PolandDepartment of Infectious and Tropical Diseases, Collegium Medicum, Jagiellonian University, 30-252 Kraków, PolandDepartment of Infectious Disease, Voivodeship Hospital, Jan Kochanowski University, 25-369 Kielce, PolandDepartment of Infectious Diseases and Hepatology, Faculty of Medicine, Nicolaus Copernicus University, 87-100 Bydgoszcz, PolandDepartment of Infectious Diseases, Medical University of Lublin, 20-059 Lublin, PolandHospital for Infectious Diseases, Warsaw Medical University, 02-091 Warszawa, PolandClinical Department of Infectious Diseases, Medical University of Silesia, 40-055 Chorzów, PolandDepartment of Internal Medicine and Hepatology, Central Clinical Hospital of Internal Affairs and Administration, 02-241 Warszawa, PolandDepartment of Basic Medical Sciences, School of Public Health in Bytom, Medical University of Silesia, 40-055 Bytom, PolandDepartment of Infectious Diseases and Hepatology, Medical University of Białystok, 15-540 Białystok, PolandDepartment of Infectious Diseases and Hepatology, Medical University of Białystok, 15-540 Białystok, PolandIntroduction: In Poland, active HCV infection affects between 0.4 and 0.5% of the population, i.e., about 150,000 people, while the number of patients with epilepsy is estimated to be 350,000–400,000. Currently available antiviral therapies show little interaction with neurological drugs. The aim of our study was to evaluate the effectiveness and safety of the treatment of chronic HCV infection in patients with coexisting epilepsy. Methods: A total of 184 epilepsy patients were selected from the group of 10,152 HCV-infected patients treated for HCV infection within the Epiter-2 database from 2015 to 2018. Comparing the effectiveness and safety of anti-HCV regimens between the patients with comorbid epilepsy and 3573 patients without comorbidities was our study’s objective. Results: The effectiveness of anti-HCV treatment was high in both the sample and the control group. No statistically significant SVR difference was observed between the sample group, with ITT = 93.5% and mITT = 95.5%, and the control group, with ITT = 95.2% and mITT = 97.5%, regardless of the genotype and the stage of liver disease at the start of therapy. The treatment was safe in patients with epilepsy. Conclusions: The effectiveness and safety of HCV treatment in patients with epilepsy are comparable to those of patients with no significant comorbidities.https://www.mdpi.com/2075-4426/13/7/1111HCV infectionepilepsyDAA treatment |
| spellingShingle | Monika Pazgan-Simon Jerzy Jaroszewicz Krzysztof Simon Beata Lorenc Marek Sitko Dorota Zarębska-Michaluk Dorota Dybowska Magdalena Tudrujek-Zdunek Hanna Berak Włodzimierz Mazur Jakub Klapaczyński Ewa Janczewska Anna Parfieniuk-Kowerda Robert Flisiak Real-World Effectiveness and Safety of Direct-Acting Antivirals in Patients with Chronic Hepatitis C and Epilepsy: An Epi-Ter-2 Study in Poland Journal of Personalized Medicine HCV infection epilepsy DAA treatment |
| title | Real-World Effectiveness and Safety of Direct-Acting Antivirals in Patients with Chronic Hepatitis C and Epilepsy: An Epi-Ter-2 Study in Poland |
| title_full | Real-World Effectiveness and Safety of Direct-Acting Antivirals in Patients with Chronic Hepatitis C and Epilepsy: An Epi-Ter-2 Study in Poland |
| title_fullStr | Real-World Effectiveness and Safety of Direct-Acting Antivirals in Patients with Chronic Hepatitis C and Epilepsy: An Epi-Ter-2 Study in Poland |
| title_full_unstemmed | Real-World Effectiveness and Safety of Direct-Acting Antivirals in Patients with Chronic Hepatitis C and Epilepsy: An Epi-Ter-2 Study in Poland |
| title_short | Real-World Effectiveness and Safety of Direct-Acting Antivirals in Patients with Chronic Hepatitis C and Epilepsy: An Epi-Ter-2 Study in Poland |
| title_sort | real world effectiveness and safety of direct acting antivirals in patients with chronic hepatitis c and epilepsy an epi ter 2 study in poland |
| topic | HCV infection epilepsy DAA treatment |
| url | https://www.mdpi.com/2075-4426/13/7/1111 |
| work_keys_str_mv | AT monikapazgansimon realworldeffectivenessandsafetyofdirectactingantiviralsinpatientswithchronichepatitiscandepilepsyanepiter2studyinpoland AT jerzyjaroszewicz realworldeffectivenessandsafetyofdirectactingantiviralsinpatientswithchronichepatitiscandepilepsyanepiter2studyinpoland AT krzysztofsimon realworldeffectivenessandsafetyofdirectactingantiviralsinpatientswithchronichepatitiscandepilepsyanepiter2studyinpoland AT beatalorenc realworldeffectivenessandsafetyofdirectactingantiviralsinpatientswithchronichepatitiscandepilepsyanepiter2studyinpoland AT mareksitko realworldeffectivenessandsafetyofdirectactingantiviralsinpatientswithchronichepatitiscandepilepsyanepiter2studyinpoland AT dorotazarebskamichaluk realworldeffectivenessandsafetyofdirectactingantiviralsinpatientswithchronichepatitiscandepilepsyanepiter2studyinpoland AT dorotadybowska realworldeffectivenessandsafetyofdirectactingantiviralsinpatientswithchronichepatitiscandepilepsyanepiter2studyinpoland AT magdalenatudrujekzdunek realworldeffectivenessandsafetyofdirectactingantiviralsinpatientswithchronichepatitiscandepilepsyanepiter2studyinpoland AT hannaberak realworldeffectivenessandsafetyofdirectactingantiviralsinpatientswithchronichepatitiscandepilepsyanepiter2studyinpoland AT włodzimierzmazur realworldeffectivenessandsafetyofdirectactingantiviralsinpatientswithchronichepatitiscandepilepsyanepiter2studyinpoland AT jakubklapaczynski realworldeffectivenessandsafetyofdirectactingantiviralsinpatientswithchronichepatitiscandepilepsyanepiter2studyinpoland AT ewajanczewska realworldeffectivenessandsafetyofdirectactingantiviralsinpatientswithchronichepatitiscandepilepsyanepiter2studyinpoland AT annaparfieniukkowerda realworldeffectivenessandsafetyofdirectactingantiviralsinpatientswithchronichepatitiscandepilepsyanepiter2studyinpoland AT robertflisiak realworldeffectivenessandsafetyofdirectactingantiviralsinpatientswithchronichepatitiscandepilepsyanepiter2studyinpoland |